Instituto Oftalmologico Fernandez-Vega S.L.
- Address
- lock Available on a paid plan
Eye Diseases
Research at Instituto Oftalmologico Fernandez-Vega S.L. focuses on ophthalmology, with studies spanning common and sight-threatening eye diseases. The trials are designed to assess new treatments, improve visual outcomes, and better understand how to manage chronic retinal and corneal conditions.
- Age-related macular degeneration, including neovascular and wet forms, with research aimed at improving vision and controlling disease activity
- Dry eye disease, evaluating therapies intended to relieve symptoms and support the eye surface
- Corneal disorders such as Fuchs endothelial corneal dystrophy, persistent corneal epithelial defects, and neurotrophic keratopathy, with a focus on healing and corneal repair
- Polypoidal choroidal vasculopathy and subretinal hyperreflective material, studying approaches that may improve retinal structure and visual function
The site’s clinical research reflects a strong interest in both retinal and corneal disease, combining efforts to test innovative eye treatments with studies that look at long-term safety, effectiveness, and patient benefit.
Retinal and Macular Research
This research area centers on neovascular age-related macular degeneration and related macular conditions. Studies here are evaluating whether newer therapies can improve best-corrected visual acuity, reduce treatment burden, and maintain vision over time in patients with chronic retinal disease.
- Neovascular age-related macular degeneration, testing treatment strategies that aim to preserve sight and control fluid-related damage
- Polypoidal choroidal vasculopathy, assessing effectiveness and durability of treatment in a distinct macular disorder
- Subretinal hyperreflective material, exploring whether therapy can help resolve retinal changes linked to vision loss
- Surabgene lomparvovec and ranibizumab-based approaches, comparing long-term control of disease and injection burden
These trials support the development of better options for patients living with chronic macular disease, especially where sustained vision improvement and fewer treatments are important goals.
Corneal and Ocular Surface Studies
The corneal program at this site includes research on Fuchs endothelial corneal dystrophy, persistent corneal epithelial defects, neurotrophic keratopathy, and dry eye disease. The main purpose is to evaluate therapies that may promote healing, improve comfort, and strengthen the eye’s surface.
- Fuchs endothelial corneal dystrophy, studying treatment options that may improve visual recovery after corneal procedures
- Persistent corneal epithelial defects, testing whether new eye treatments can support lasting corneal re-epithelialization
- Neurotrophic keratopathy, examining therapies intended to enhance corneal healing and safety
- Dry eye disease, evaluating eye drops designed to reduce irritation and improve ocular surface health
Overall, the work in this area is aimed at helping patients with difficult-to-treat surface disease by finding options that improve healing and day-to-day eye comfort.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Instituto Oftalmologico Fernandez-Vega S.L.
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12 Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy | Kowa Research Institute Inc. | Phase III | Not Recruiting | Aug 2023 | Oct 2025 |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ranibizumab | 3 | Unknown | 2021-10-22 | 2025-12-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.